During this period, combination therapy with cytokines (e.g., IL-2) or vaccines significantly enhances T-cell reactivation, improving tumor inhibition rates by approximately 50% compared to PD-1 blockade alone (265). This evidence concerns the gene PDCD1 and neoplasm.